Norges Bank
ZBIO

Norges Bank’s Zenas BioPharma ZBIO Stock Holding History

Norges Bank’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-66,202
Closed -$542K – 1873
2024
Q4 		$542K Sell
66,202
-8,798
-12% -$137K ﹤0.01% 1790
2024
Q3 		$1.27M Buy
+75,000
New +$1.35M ﹤0.01% 1707

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Norges Bank's ZBIO Position: Q1 2025 in Review

Norges Bank sold out of Zenas BioPharma (ZBIO) in Q1 2025, closing a stake of 66,202 shares — an estimated $542K sold.

Norges Bank first reported a position in ZBIO in Q3 2024 and held it in 2 quarters. The position peaked at $1.27M in Q3 2024. 67 funds tracked by Wall St. Rank hold ZBIO as of Q1 2025.

  • Norges Bank reported no remaining Zenas BioPharma position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 66,202 Zenas BioPharma shares in Q1 2025, an estimated $542K.
  • Norges Bank first reported a position in Zenas BioPharma in Q3 2024 and held it in 2 quarters.
  • Norges Bank's Zenas BioPharma position peaked at $1.27M in Q3 2024.
  • 67 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.